DF/HCC Program Affiliation

Head and Neck Cancer, Leader
Translational Pharmacology and Early Therapeutic Trials

DF/HCC Associations

Member, Center Scientific Council

Research Abstract

Clinical and Translational Research Interests in Head and Neck Cancer: The Head and Neck Oncolgy Program is dedicated to improving the treatment and understanding of head and neck cancer. We are involved in numerous studies that include investigational therapy of squamous cell cancer, nasopharyngeal cancer, salivary gland tumors and other related cancers in the head and neck. Therapeutic interventions include chemotherapy, gene therapy, chemoradiotherapy, and chemoprevention in Phase I, II and III studies. We are investigating the molecular epidemiology of head and neck cancer by studying molecular corelates of susecptibility of different clinical grups to this disease. We are also investigating the role of CD40 in signal transduction in Squamous Cancer of the Head an Neck using in vivo and in vitro models. Basic Laboratory Research Interests: The Human Monoclonal Antibody Laboratory uses human monoclonal antibodies to study and treat a variety of human diseases. Since many animal models do not accurately reflect human responses, this provides a unique opportunity understand the pathogenesis of human disease and develop new human therapeutic reagents. Our laboratory is studying a variety of human infectious disease and human cancers. We have amajor focus on the human immune response to HIV and are investigating the possible role of theses antinbodies in the control or progression of this disease. We are also studying antibody responses to Pseudomonas Aureginosa and Group B Streptococus infection. We are using our technology to study the antibody response to melanoma and prostate cancer in selected patients being treated with immunomodulatory therapies.

Publications

• Wirth LJ, Haddad RI, Posner MR.Progress and perspectives in chemoprevention of head and neck cancer.Expert Rev Anticancer Ther 2003 Jun;3(3):339-55.
  12820777
• Haddad RI, Wirth L, Posner MR.Integration of chemotherapy in the curative treatment of locally advanced head and neck cancer.Expert Rev Anticancer Ther 2003 Jun;3(3):331-8.
  12820776
• Haddad R, Tishler RB, Norris CM, Mahadevan A, Busse P, Wirth L, Goguen LA, Sullivan CA, Costello R, Case MA, Posner MR.Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-m
  12604730
• Haddad R, Colevas AD, Tishler R, Busse P, Goguen L, Sullivan C, Norris CM, Lake-Willcutt B, Case MA, Costello R, Posner M.Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of th
  12518365
• Ringström E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey KT.Human papillomavirus type 16 and squamous cell carcinoma of the head and neck.Clin Cancer Res 2002 Oct;8(10):3187-92.
  12374687
• Posner MR, Glisson B, Frenette G, Al-Sarraf M, Colevas AD, Norris CM, Seroskie JD, Shin DM, Olivares R, Garay CA.Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell
  11181674
• Cavacini LA, Peterson JE, Nappi E, Duval M, Goldstein R, Mayer K, Posner MR.Minimal incidence of serum antibodies reactive with intact primary isolate virions in human immunodeficiency virus type 1-infected individuals.J Virol 1999 Nov;73(11):9638-41.
  10516076
• Posner MR, Cavacini LA, Upton MP, Tillman KC, Gornstein ER, Norris CM.Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines.Clin Cancer R
  10473114